IMNN Imunon Inc

Price (delayed)

$1.38

Market cap

$12.97M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.02

Enterprise value

$12.13M

Celsion is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including immunotherapies and DNA-based therapies; and a platform for the development of ...

Highlights
IMNN's debt has plunged by 80% YoY and by 7% from the previous quarter
The company's EPS rose by 50% YoY and by 6% QoQ
The company's gross profit has shrunk by 100% YoY
Imunon's revenue has plunged by 100% YoY

Key stats

What are the main financial stats of IMNN
Market
Shares outstanding
9.4M
Market cap
$12.97M
Enterprise value
$12.13M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.53
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$20.1M
EBITDA
-$19.39M
Free cash flow
-$21.22M
Per share
EPS
-$2.02
Free cash flow per share
-$2.26
Book value per share
$0.9
Revenue per share
$0
TBVPS
$1.52
Balance sheet
Total assets
$14.32M
Total liabilities
$5.83M
Debt
$1.51M
Equity
$8.5M
Working capital
$7.28M
Liquidity
Debt to equity
0.18
Current ratio
2.51
Quick ratio
2.04
Net debt/EBITDA
0.04
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-84.1%
Return on equity
-122.7%
Return on invested capital
-180.6%
Return on capital employed
-211.4%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IMNN stock price

How has the Imunon stock price performed over time
Intraday
10.4%
1 week
-1.43%
1 month
23.21%
1 year
12.2%
YTD
102.94%
QTD
18.97%

Financial performance

How have Imunon's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$20.36M
Net income
-$18.85M
Gross margin
N/A
Net margin
N/A
The company's gross profit has shrunk by 100% YoY
Imunon's revenue has plunged by 100% YoY
The net income has grown by 39% YoY and by 3.4% from the previous quarter
IMNN's operating income is up by 18% YoY and by 3.2% QoQ

Growth

What is Imunon's growth rate over time

Valuation

What is Imunon stock price valuation
P/E
N/A
P/B
1.53
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 50% YoY and by 6% QoQ
IMNN's price to book (P/B) is 85% higher than its last 4 quarters average of 0.8 and 14% higher than its 5-year quarterly average of 1.3
The equity has dropped by 68% year-on-year and by 37% since the previous quarter
Imunon's revenue has plunged by 100% YoY

Efficiency

How efficient is Imunon business performance
IMNN's ROIC has shrunk by 79% YoY and by 42% QoQ
Imunon's return on assets has decreased by 44% YoY and by 26% QoQ
The ROE has contracted by 43% YoY and by 25% from the previous quarter

Dividends

What is IMNN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IMNN.

Financial health

How did Imunon financials performed over time
The total assets is 146% more than the total liabilities
The total assets has plunged by 66% YoY and by 35% from the previous quarter
The company's total liabilities has shrunk by 62% YoY and by 32% QoQ
IMNN's debt is 82% less than its equity
IMNN's debt has plunged by 80% YoY and by 7% from the previous quarter
The equity has dropped by 68% year-on-year and by 37% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.